Most studies of HIV-1 drug resistance have examined subtype B viruses; fewer data are available from developing countries, where non-B subtypes predominate. We determined the prevalence of mutations at protease and reverse transcriptase drug resistance positions in antiretroviral drug-naive individuals in southern India. The pol region of the genome was amplified from plasma HIV-1 RNA in 50 patients. All sequences clustered with HIV-1 subtype C. All patients had at least one protease and/or RT mutation at a known subtype B drug resistance position. Twenty percent of patients had mutations at major protease inhibitor resistance positions and 100% had mutations at minor protease inhibitor resistance positions. Six percent and 14% of patients had mutations at nucleoside reverse transcriptase inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance positions, respectively. Larger scale studies need to be undertaken to better define the genotypic variation of circulating Indian subtype C viruses and their potential impact on drug susceptibility and clinical outcome in treated individuals. 301 M UCH OF OUR KNOWLEDGE regarding antiretroviral (ARV) drug resistance and naturally occurring genotypic variation in HIV-1 protease and reverse transcriptase (RT) is derived from studies focusing on subtype B strains in Europe and North America. 1 Yet Ͼ90% of HIV-1-infected individuals reside in Asia and Africa, where non-B subtypes predominate. Generic ARV drugs have become widely available in India, and are well tolerated and efficacious. 2 The most common regimen is a three-drug combination of lamivudine, nevirapine, and zidovudine or stavudine. Of the ϳ7000 HIV-1-infected individuals currently monitored by physicians at the Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE, Chennai, India), nearly 30% are receiving ARVs. Despite widespread ARV use, little information is available on the prevalence of HIV-1 drug resistance in India. The goal of the present study was to genotypically characterize HIV-1 protease and RT genes in drug-naive southern Indian patients. As treatment programs are expanded, sequences obtained before ARV therapy exposure provide baseline rates of polymorphism at positions thought to be related or not related to drug resistance. This sets the stage for evaluation of the transmission of resistance, 3,4 choice of initial treatment 5 and identification of the genetic changes resulting from treatment failure. 6 The study population consisted of HIV-1-infected drug-naive individuals who were receiving their medical care at the YRG CARE clinics in Chennai, India in 2002. Individuals completed a detailed questionnaire of demographic information, sexual behavior, and treatment history.
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Sequencing of protease and RT was carried out as described previously. 3 Briefly, viral RNA was extracted from plasma (QIAamp viral RNA extraction kit; Qiagen, Valencia, CA) and reverse transcribed to complementary DNA (cDNA). Protease and RT were amplified from cDNA by single or nested polymerase chain reaction (PCR) with protease and RT primers and sequenced on an automated DNA sequencer. Single cycle reaction primers were as follows: protease PR1 (nucleotides 2147-2168: 5Ј-ACC AGA GCC AAC AGC CCC ACC A) and PR2 (nucleotides 2587-2609: 5Ј-CTT TTG GGC CAT CCA TTC CTG GC); and reverse transcriptase RT1 (nucleotides 2504-2482: 5Ј-TAG GAC CTA CAC CTG TCA ACA TA) and RT6 (nucleotides 3279-3255: 5Ј-TAG GCT GTA CTG TCC ATT TAT CAG G). The PCR conditions were as follows: 95°C for 1 min followed by 35 cycles at 95°C for 15 sec, 65°C for 30 sec, and 72°C for 45 sec for PR and 95°C for 15 sec, 60°C for 30 sec, and 72°C for 1 min for RT. Products from firstround PCR were first analyzed on an ethidium bromide-stained agarose (1%) gel. If the correct amplicon was visible on the gel it was column purified with a PCR purification kit (Qiagen). Those samples that were not detected after the first-round PCR were subjected to a second round of PCR. The primers used for nested PCR were PR2 and PR3 (nucleotides 2233-2255: 5Ј-GAAGCAGGAGCCGATAGACAAGG) for protease and R3 (nucleotides 2504-2484: 5Ј-TAGGCTGTACTGTCCATT-TATCAGG) and RT6 for reverse transcriptase. The PCR conditions were as follows: 95°C for 1 min followed by 25 cycles at 95°C for 15 sec, 55°C for 30 sec, and 72°C for 45 sec for PR and 95°C for 15 sec, 55°C for 30 sec, and 72°C for 1 min for RT. The amplicon was again checked on an agarose gel and subsequently column purified. The column-purified PCR products were sequenced with an ABI PRISM 3100 DNA sequencer (Applied Biosystems, Foster City, CA). The cycle sequencing was carried out with AmpliTaq and dye-labeled terminators (Applied Biosystems).
Protease and RT mutations were defined as differences from consensus B, according to the Stanford Drug Resistance Database rules (http://hivdb.stanford.edu). Nucleotide mixtures of wild-type and mutation were classified as mutation. Phylogenetic analysis was performed by neighbor joining with Jukes and Cantor distance estimation within TREECON for Windows, version 1.3b (http://bioinformatics.psb.ugent.be/psb/ Userman/treeconw.html) and with bootscanning (Simplot, http://sray.med.som.jhmi.edu/RaySoft/SimPlot/) to rule out recombination. Genetic nucleic acid distances were measured by Synscan with a weighted scoring matrix. 7 Reference sequences used and their accession numbers were U455 (M62320, subtype A), CM240 (U54771, CRF01_AE), IbNG (L39106, CRF02_AG), HXB2 (K03455, subtype B), C2220 (U46016, subtype C), NDK (M27323, subtype D), 93BR020 (AF005494, subtype F), SE6165 (AF061642, subtype G), 90CR056 (AF005496, subtype H), SE9173c (AF082394, subtype J), and 97EQTB11C (AJ249235, subtype K). Samples were obtained from 50 sequential patients who met the inclusion criteria. Thirty-three of 50 (66%) were males, and the mean age was 34 years (range, 20-61 years). Eighty-eight percent of individuals contracted HIV-1 infection by heterosexual transmission and 12% by blood transfusion. The median CD4 ϩ T lymphocyte count and plasma HIV-1 RNA level were 208 cells/l (range, 16-790 cells/l) and 5.1 log 10 copies/ml (range, 2.4-Ͼ5.9 copies/ml), respectively ( Table 1) .
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Of the 50 viral isolates, 10 (20%) had mutations at known major subtype B protease drug resistance positions and all had mutations at known minor subtype B protease drug resistance positions. The most common patterns of minor mutated positions were 36, 63, and 93 (39 of 50, 78%); and 20, 36, 63, and 93 (5 of 50, 10%). Among the major drug resistance positions, a mutation at position 82 (V82I) was the most common (9 of 50, 18%) ( Table 2 ). In the RT, 8 (16%) persons had mutations at known subtype B drug resistance positions: 3 (6%) at nucleoside reverse transcriptase inhibitor (NRTI) and 7 (14%) at nonnucleoside reverse transcriptase inhibitor (NNRTI) positions. Two persons (4%) had mutations at NRTI and NNRTI subtype B drug resistance positions. The most common RT mutations were at position 103 (K103E/R, 4 of 50, 8%) ( Table 3) .
Mutations at 10 protease positions and 3 RT positions that have been described as treatment related in subtype B 8, 9 were also noticed in our cohort. Although these mutations are associated with treatment, they are commonly encountered in naive patients, particularly in those infected with non-B subtypes. These included protease positions 89 (occurring in 41 sequences), 13 All pol sequences of the study patients clustered with subtype C reference sequences with a high bootstrap value ( Fig.  1 ) with no evidence of recombination. Two married couples with presumed heterosexual transmission were identified in this cohort: The first was one of four pairs of monophyletic sequences with bootstrap values Ͼ70% (YRG19 and YRG25); and the second had a bootstrap value of 57% (YRG11 and YRG16). Genetic distances between the sequences of the first and second couples were 4.4 and 2.9%, respectively, both at the lower end of the spectrum of genetic distances between all pairs (range, 2.6-8.6%). Epidemiologic information on other monophyletic pairs of sequences was not available. Resistance to ARV drugs is a global problem, and is perceived as one of the main obstacles to successful long-term HIV-1 treatment. 4, 10 India is experiencing a rapid and extensive spread of HIV-1 infection and is reported to have entered the third stage of the epidemic (http://www.who.int/emc-hiv/). Because of reduced cost of generic drugs, a considerable increase in ARV use is being observed. Current knowledge on drug resistance in India is limited. 11 Here we present sequence data and analyze the mutations at drug resistance positions in protease and RT sequences from ARV-naive, subtype C-infected, southern Indian patients. We observed mutations at major subtype B drug resistance positions (protease positions 24, 46, and 82 and RT positions 67, 103, and 210), as well as extensive naturally occurring polymorphisms in the protease, particularly at positions 36, 63, and 93, in agreement with earlier reports. 1, [12] [13] [14] The significance of mutations at known drug resistance positions as well as at positions more recently related to treatment, as described here, with respect to drug susceptibility in subtype C virus, is not well defined. None of the protease or RT inhibitor-associated mutations observed in these naive subtype C sequences have individually been shown to confer significant levels of resistance. However, more extensive studies are warranted to determine whether the subtype C genetic backbone provides different routes to drug resistance, or may modify the evolution and the effects of drug-selected mutations, possibly by compensatory changes in the enzyme. In a growing number of reports, subtle differences in treatment response and the selection of resistance have been identified in comparing non-B infections with the more robust subtype B experience. 1, 6, 15 This study, although limited to 50 drug-naive individuals, offers some reassurance that contemporary subtype C viruses in southern India are not likely to exhibit high levels of drug resistance. This is consistent with evidence from other non-subtype B studies. Despite the considerable HIV-1 genetic variability at subtype B drug resistance positions, the results of treatment trials and phenotypic studies indicate that most baseline mutations at resistance positions that are not specifically associated with resistance, usually do not adversely affect the response to ARV drugs. 5 Thus, to date, most non-B HIV-1 from ARV-naive patients in Africa, South America, and Europe are generally as sensitive as are subtype B viruses to ARVs. 3, 5, 15 Ongoing sequence analysis of subtype C isolates from drugnaive and treated individuals will determine whether the naturally occurring variability at drug resistance and treatment-related positions contributes to selection of drug resistance and, ultimately, to clinical outcome of ARV therapy.
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Although HIV-1 drug resistance is usually acquired during failure of ARV therapy, drug-resistant strains are also transmitted between individuals. In the United States and Europe nearly 10% of new infections are due to HIV-1 isolates harboring resistance to at least one of the three classes of anti-HIV drugs, and studies have shown that this continues to increase. 3, 8 The results presented here argue against evidence for transmitted drug resistance at present. However, larger studies and continuous surveillance are needed among drug-naive populations, particularly as access to treatment and availability of ARVs increase for the estimated 5-7 million people infected with HIV-1 in India.
